Quince Therapeutics, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises eDSP, which is in Phase 3, for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consist of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising kit medical devices, syringe kit, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. The company was incorporated in 2012 and is headquartered in South San Francisco, California. Show more

611 Gateway Boulevard, South San Francisco, CA, 94080, United States

https://quincetx.com

Biotechnology

Healthcare

Start AI Chat

Market Cap

20.93M

52 Wk Range

$0.79 - $45.50

Previous Close

$1.07

Open

$1.07

Volume

1,258,564

Day Range

$1.01 - $1.10

Enterprise Value

3.074M

Cash

18.16M

Avg Qtr Burn

-7.627M

Insider Ownership

3.19%

Institutional Own.

9.98%

Qtr Updated

03/31/26

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Sirolimus/Rapamycin (LAM-001) (mTOR Inhibitor) Details Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)	Phase 2b Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Rapamycin/Sirolimus (LAM-001) (mTOR Inhibitor) Details Pulmonary Hypertension Associated With Interstitial Lung Disease	Phase 2b Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Rapamycin/Sirolimus (LAM-001) (mTOR Inhibitor) Details Bronchiolitis Obliterans Syndrome	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Sirolimus/Rapamycin (LAM-001) (mTOR Inhibitor) Details Bronchiolitis Obliterans Syndrome	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Sirolimus/Rapamycin (LAM-001) (mTOR Inhibitor) Details Sarcoidosis-Associated Pulmonary Hypertension	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Rapamycin/Sirolimus (LAM-001) (mTOR Inhibitor) Details Sarcoidosis-Associated Pulmonary Hypertension	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Rapamycin/Sirolimus (LAM-001) (mTOR Inhibitor) Details Pulmonary Arterial Hypertension	Phase 2a Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Atuzaginstat (COR388) / Lysine gingipain inhibitor Details Alzheimer's disease, Neurological disorder	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Atuzaginstat (COR388) (Lysine gingipain inhibitor) Details Periodontal disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
COR588 (Lysine gingipain inhibitor) Details Mental health, Alzheimer's disease, Neurological disorder	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Atuzaginstat (COR388) / Lysine gingipain inhibitor Details Parkinson's disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
EryDex Details Rare genetic disease, Neurological disorder, Ataxia Telangiectasia	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
EryDex/Dexamethasone Sodium Phosphate (eDSP) (Encapsulated Corticosteroid) Details Duchenne Muscular Dystrophy	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.